EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy

Yinxian Yang iD, Shenqiang Wang, Xueying Shi, Xudong Chen, Ruyi Zhou, Tao Sheng iD, Xiaofeng Chen, Jinpeng Han iD, Yan Xu, Qing Wu, Yuqi Zhang, Hongjun Li iD und 2 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2419694123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Yinxian Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Blood Platelets, Immunotherapy, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), Fujian Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-targeted delivery of oncolytic viruses (OVs) via systemic administration could not only expand virotherapy beyond primary tumors to widespread metastases, but also improve clinical adherence and convenience. We here engineer megakaryocytes encapsulating oncolytic adenovirus type 5 (M-Ad5) to produce oncolytic platelets in vivo by leveraging the thrombopoiesis process. Upon intravenous administration, M-Ad5 travels through the lungs, where it can release OVs-harbored therapeutic platelets into circulation under pulmonary turbulence microenvironments. Under the shelter of platelets, OVs resist inactivation by neutralizing antibodies and actively target widespread noninjectable cancer lesions. Intravenous infusion of M-Ad5 to mice with A549 lung cancer could significantly inhibit tumor growth and prolong survival. In multiple mouse tumor models, M-Ad5 induced a robust antitumor immune response by reprogramming the immunosuppressive tumor microenvironment, and potentiated the response to immune checkpoint inhibitors by recruiting more immune cells. We demonstrated that M-Ad5 in combination with PDL1 inhibitors activated tumor antigen-specific CD8 + T cells and memory T cells, thereby suppressing the growth of CT26 colorectal cancer metastasis, and preventing postsurgical B16F10 cancer recurrence and metastatic spread, as well as providing long-term immune protection against the rechallenged tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsImmunotherapyOncolytic VirotherapyOncolytic VirusesMegakaryocytesAnimalsMiceHumansTumor MicroenvironmentMice, Inbred C57BLCell Line, TumorInfusions, IntravenousAdenoviridaeLung NeoplasmsFemaleB7-H1 AntigenCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

cancer immunotherapycell therapydrug deliveryoncolytic virusplatelet engineering

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, China.
  • Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 36…
  • State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
  • Blood Center of Zhejiang Province, Hangzhou 310052, China.
  • Jinhua Institute of Zhejiang University, Jinhua 321299, China.
  • Department of Burns and Wound Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.

ORCID-Profile: Yinxian Yang, Tao Sheng, Jinpeng Han, Hongjun Li, Zhen Gu

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)
  • Fujian Provincial Natural Science Foundation of China
  • Pioneer and Leading Goose R&D Program of Zhejiang
  • Natural Science Foundation of Zhejiang Province
  • Xiang An Biomedicine Laboratory

Zitieren

APA

Yang, Y., Wang, S., Shi, X., Chen, X., Zhou, R., Sheng, T., Chen, X., Han, J., Xu, Y., Wu, Q., Zhang, Y., Li, H., Yu, J., & Gu, Z. (2026). Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2419694123

Vancouver

Yang Y, Wang S, Shi X, Chen X, Zhou R, Sheng T, et al. Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2419694123

BibTeX
@article{Yang2026,
  author = {Yang, Yinxian and Wang, Shenqiang and Shi, Xueying and Chen, Xudong and Zhou, Ruyi and Sheng, Tao and Chen, Xiaofeng and Han, Jinpeng and Xu, Yan and Wu, Qing and Zhang, Yuqi and Li, Hongjun and Yu, Jicheng and Gu, Zhen},
  title = {Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2419694123}
}
Kostenlos starten →